PulteGroup, Inc. vs Veeva Systems — how do they compare? PulteGroup, Inc. trades at $118.95 (market cap $22.87B), while Veeva Systems trades at $261 (market cap $42.88B). The key difference: Veeva Systems is the larger of the two by market cap, and PulteGroup, Inc. pays a 0.87% dividend while Veeva Systems pays none. Which is the better fit depends on your goals.
| PHM | VEEV | |
|---|---|---|
Market Cap | $22.87B | $42.88B |
Sector | Consumer Cyclical | Technology |
52-Week High | $142.56 | $306.22 |
52-Week Low | $110.11 | $151.43 |
Enterprise Value | $23.28B | $35.79B |
Dividend Yield | 0.87% | — |
Signals from Pluang's Aura AI — not financial advice
PulteGroup (PHM) trades at $120.07, down 3.52% on the day amid a bearish technical signal. The stock shows mixed fundamentals with a P/E of 12.26 and net income margin of 11.62%, but recent earnings missed expectations in two of the last three quarters. Positive cash flow of $355.10M in 2025 and expansion into Northwest Florida provide operational strength, though rising mortgage rates pose headwinds.
The outlook is cautious with analyst consensus leaning buy (47.73%) and a $137.57 price target suggesting 14.6% upside. Key risks include housing affordability pressures from higher yields and volatile earnings performance. The stock's current level near support at $119 offers a potential entry, but macroeconomic sensitivity warrants careful monitoring.
No Aura AI signal available yet.
Trailing returns across standard periods
PulteGroup Inc is one of the largest homebuilders in the United States, operating in 40 markets across 23 states. The company mainly builds single-family detached homes (85% of unit sales) and offers products to entry-level, move-up, and active-adult buyers. PulteGroup offers homebuyers mortgage financing and title agency services through its financial services segment. The company is headquartered in Atlanta.
Read more on PHM →Veeva Systems provides cloud software, data, and services for the life sciences industry. Its applications support functions across clinical research, regulatory operations, quality, safety, and commercial teams.
Read more on VEEV →